1. Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor. 
2. Diagnosis of acute promyelocytic leukemia 
3. Diagnosis of chronic myelogenous leukemia (CML) in blast crisis 
4. AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment 
5. AML or antecedent MDS secondary to prior chemotherapy 
6. Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy 
7. Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant 
8. Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor. 
9. Patients who have previously received AC220 
10. Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical assessment) 
11. Major surgery within 4 weeks prior to enrollment in the study 
12. Radiation therapy within 4 weeks prior to, or concurrent with study 
13. Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient. 
14. Uncontrolled or significant cardiovascular disease 
15. Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential 
16. Men who are unwilling to use contraception if their partners are of childbearing potential 
17. Active, uncontrolled infection 
18. Human immunodeficiency virus positivity 
19. Active hepatitis B or C or other active liver disease 
20. History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission       
    

NCT00989261_exc_T1
Value
over the age of 85 years
NCT00989261_exc_T2
Person
age
NCT00989261_exc_T5
Condition
acute promyelocytic leukemia
NCT00989261_exc_T6
Condition
chronic myelogenous leukemia (CML)
NCT00989261_exc_T7
Condition
blast crisis
NCT00989261_exc_T8
Condition
AML
NCT00989261_exc_T9
Qualifier
in relapse
NCT00989261_exc_T10
Qualifier
refractory
NCT00989261_exc_T11
Temporal
after 3 or more previous lines of chemotherapy
NCT00989261_exc_T12
Multiplier
3 or more
NCT00989261_exc_T13
Temporal
previous
NCT00989261_exc_T14
Procedure
lines of chemotherapy
NCT00989261_exc_T15
Scope
in relapse or refractory
NCT00989261_exc_T16
Condition
AML
NCT00989261_exc_T17
Condition
MDS
NCT00989261_exc_T18
Temporal
antecedent
NCT00989261_exc_T20
Temporal
prior
NCT00989261_exc_T21
Condition
chemotherapy
NCT00989261_exc_T19
Scope
AML or antecedent MDS
NCT00989261_exc_T22
Condition
toxicity
NCT00989261_exc_T23
Qualifier
non-hematological
NCT00989261_exc_T24
Qualifier
clinically significant
NCT00989261_exc_T26
Value
Grade >1
NCT00989261_exc_T27
Measurement
NCI CTCAE v4
NCT00989261_exc_T28
Qualifier
Grade >1 by NCI CTCAE v4
NCT00989261_exc_T29
Procedure
chemotherapy
NCT00989261_exc_T30
Temporal
prior
NCT00989261_exc_T31
Temporal
within 100 days of transplant
NCT00989261_exc_T32
Condition
HSCT
NCT00989261_exc_T33
Temporal
have had
NCT00989261_exc_T34
Procedure
transplant
NCT00989261_exc_T35
Reference_point
transplant
NCT00989261_exc_T36
Drug
immunosuppressive drugs
NCT00989261_exc_T37
Qualifier
clinically significant
NCT00989261_exc_T39
Condition
graft-versus-host disease
NCT00989261_exc_T40
Procedure
treatment
NCT00989261_exc_T41
Mood
requiring
NCT00989261_exc_T42
Qualifier
>Grade 1
NCT00989261_exc_T43
Qualifier
non hematological
NCT00989261_exc_T44
Qualifier
persistent
NCT00989261_exc_T45
Multiplier
persistent
NCT00989261_exc_T46
Condition
toxicity
NCT00989261_exc_T47
Procedure
transplant
NCT00989261_exc_T48
Temporal
still
NCT00989261_exc_T49
Condition
central nervous system (CNS) leukemia
NCT00989261_exc_T51
Drug
AC220
NCT00989261_exc_T52
Condition
Disseminated intravascular coagulation (DIC)
NCT00989261_exc_T53
Procedure
Major surgery
NCT00989261_exc_T54
Temporal
within 4 weeks prior to enrollment
NCT00989261_exc_T55
Reference_point
enrollment
NCT00989261_exc_T56
Procedure
Radiation therapy
NCT00989261_exc_T57
Temporal
within 4 weeks prior to study
NCT00989261_exc_T58
Temporal
concurrent with study
NCT00989261_exc_T59
Reference_point
study
NCT00989261_exc_T60
Scope
within 4 weeks prior to, or concurrent with study
NCT00989261_exc_T61
Condition
prolong QT/QTc interval
NCT00989261_exc_T62
Drug
drugs that prolong QT/QTc interval
NCT00989261_exc_T63
Drug
CYP3A4 inhibitors
NCT00989261_exc_T64
Drug
antibiotics
NCT00989261_exc_T65
Drug
antifungals
NCT00989261_exc_T66
Drug
antimicrobials
NCT00989261_exc_T67
Qualifier
that prolong QT/QTc interval
NCT00989261_exc_T68
Negation
with the exception of
NCT00989261_exc_T69
Scope
antibiotics, antifungals, and other antimicrobials
NCT00989261_exc_T70
Scope
drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors
NCT00989261_exc_T71
Condition
cardiovascular disease
NCT00989261_exc_T72
Qualifier
Uncontrolled
NCT00989261_exc_T73
Qualifier
significant
NCT00989261_exc_T74
Scope
Uncontrolled or significant
NCT00989261_exc_T75
Condition
pregnant
NCT00989261_exc_T76
Condition
lactating
NCT00989261_exc_T77
Mood
unwilling
NCT00989261_exc_T78
Condition
childbearing potential
NCT00989261_exc_T79
Condition
contraception
NCT00989261_exc_T80
Person
Men
NCT00989261_exc_T81
Mood
unwilling
NCT00989261_exc_T82
Drug
contraception
NCT00989261_exc_T83
Observation
their partners are of childbearing potential
NCT00989261_exc_T85
Condition
infection
NCT00989261_exc_T86
Qualifier
uncontrolled
NCT00989261_exc_T87
Temporal
Active
NCT00989261_exc_T88
Condition
Human immunodeficiency virus
NCT00989261_exc_T89
Measurement
Human immunodeficiency virus
NCT00989261_exc_T90
Value
positivity
NCT00989261_exc_T91
Condition
hepatitis B
NCT00989261_exc_T92
Condition
hepatitis C
NCT00989261_exc_T93
Temporal
Active
NCT00989261_exc_T94
Condition
liver disease
NCT00989261_exc_T95
Temporal
active
NCT00989261_exc_T96
Scope
hepatitis B or C
NCT00989261_exc_T97
Condition
cancer
NCT00989261_exc_T98
Observation
History
NCT00989261_exc_T99
Condition
skin cancer
NCT00989261_exc_T100
Qualifier
nonmelanotic
NCT00989261_exc_T101
Qualifier
Stage 1 cervix
NCT00989261_exc_T102
Negation
except